Arnatar Therapeutics
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Arnatar Therapeutics - overview
Established
2022
Location
Shanghai, -, China
Primary Industry
Biotechnology
About
Based in Shanghai, China, and founded in 2022, Arnatar Therapeutics operates as a biopharmaceutical developer that focuses on the development of innovative nucleic acid drugs. The founding team includes Dr. Xuehai Liang, a former Ionis technology leader, and Dr. Yanfeng Wang, a former DMPK and clinical pharmacology leader at Merck, Novartis, and Ionis.
In April 2024, Arnatar Therapeutics raised over USD 52 million in series A funding co-led by new investors Eight Roads Ventures, F-Prime Capital, and 3E Bioventures Capital, with participation from other new investors Huajin Capital, Gaorong Ventures, Jifeng Ventures, New Alliance Capital, Yijing Investment, Legend Star, Hongsheng Capital, and Transfar Group. Other unspecified investors also participated in the round, etc. Arnatar Therapeutics is dedicated to the development of innovative drugs for the treatment of liver-targeted and extra-hepatic targeting of nucleic acids, based on antisense technology. The company has developed more than 10 antisense drugs.
It has also built the siRNA technology platform and the ASO technology platform, Advanced Antisense Platform, that regulates protein expression in both directions. The drugs can be used in curing common metabolic diseases and severe rare diseases. The company generates revenue by developing antisense drugs. The company will accelerate its drug pipeline and advance clinical trials, as well as the operation of its Chinese company.
Current Investors
Apricot Capital, Eight Roads Ventures, F-Prime Capital
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Healthcare IT, Pharmaceutical Research & Development, Specialty Pharmaceuticals
Website
www.arnatar.com
Verticals
HealthTech
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.